All In Biotech

Drug Trial Radar · NCT03960671

Therapeutic Drug Monitoring of Anxiolytics in Children

Last checked: Nov 19, 2026Latest source record: May 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

500

Planned (sponsor's estimate)

Start

Aug 1, 2018

Primary completion

Dec 31, 2022

Study completion Dec 31, 2022

Sponsor

Lead sponsor
Wei ZhaoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 23, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 29 days, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, the therapeutic drug monitoring of anxiolytics is carried out among children to obtain the drug concentration, clinical efficacy and safety data of children patients in different gender and age groups. Then the investigators analyze the relationship between blood drug concentration and efficacy and safety, and provide recommendations for the treatment window of anxiolytics in Chinese children.

Conditions

  • Anxiolytics

Interventions

  • Midazolam/diazepam/propofolDrug

    Therapeutic drug monitoring of anxiolytics

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma drug concentrationTime frame: Through study completion, an average of 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shandong Provincial Qianfoshan Hospital

    Ji'nan, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.